Neal D Shore, Daniel J George, Daniel E Spratt, Jose De La Cerda
{"title":"The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer.","authors":"Neal D Shore, Daniel J George, Daniel E Spratt, Jose De La Cerda","doi":"10.1080/14796694.2025.2470108","DOIUrl":null,"url":null,"abstract":"<p><p>Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly co-prescribed with complementary oncologic therapies or agents targeting associated comorbidities (e.g. cardiovascular disease). In this podcast, we review studies which evaluate relugolix with concomitant next-generation hormonal therapies (abiraterone, apalutamide, and enzalutamide), chemotherapy (docetaxel), radiotherapy, and common cardiovascular medications (antihypertensives, antithrombotics, and lipid‑lowering agents). Based on these studies, these therapies do not appear to affect relugolix efficacy and no new safety concerns were reported.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"883-887"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952125/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2470108","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Relugolix is a once-daily oral gonadotropin-releasing hormone antagonist that was approved by the U.S. Food and Drug Administration in 2020 for the treatment of advanced prostate cancer. Relugolix is commonly co-prescribed with complementary oncologic therapies or agents targeting associated comorbidities (e.g. cardiovascular disease). In this podcast, we review studies which evaluate relugolix with concomitant next-generation hormonal therapies (abiraterone, apalutamide, and enzalutamide), chemotherapy (docetaxel), radiotherapy, and common cardiovascular medications (antihypertensives, antithrombotics, and lipid‑lowering agents). Based on these studies, these therapies do not appear to affect relugolix efficacy and no new safety concerns were reported.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
